JNJ vs PFE

For growth investors, Johnson & Johnson (JNJ) is the stronger pick with 6.

0% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Pfizer Inc. (PFE) offers the better valuation at 17. 4x trailing P/E (8. 0x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 17. 4x versus Johnson & Johnson at 22. 2x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 0x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +62.

2%, compared to -17. 5% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: JNJ returned +144. 9% versus PFE's +22. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at -0.

03β versus Pfizer Inc. 's 0. 34β — meaning PFE is approximately -1193% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 59% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Johnson & Johnson (JNJ) is pulling ahead at 6.

0% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Johnson & Johnson grew EPS 90. 5% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, JNJ leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 28.

5% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 28. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 27. 2% versus 24. 7% for PFE. At the gross margin level — before operating expenses — JNJ leads at 72. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 0x forward P/E versus 21. 2x for Johnson & Johnson — 13. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PFE: 13. 0% to $26. 75.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 7. 3%, versus 2. 1% for Johnson & Johnson (JNJ).

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

03), 2. 1% yield, +144. 9% 10Y return). Both have compounded well over 10 years (JNJ: +144. 9%, PFE: +22. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: JNJ is a large-cap quality compounder stock; PFE is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.